Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2019-06-27 Regulatory Filings
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
Theranexus and Beyond Batten Disease Foundation (BBDF) announce agreement in principle to develop and market Batten disease drug candidate BBDF 101
Regulatory Filings Classification · 98% confidence The document is a press release dated June 27, 2019, announcing an 'agreement in principle (term sheet)' between Theranexus and Beyond Batten Disease Foundation (BBDF) regarding the development and marketing of a drug candidate (BBDF 101). It details the terms of the partnership, the disease being targeted (Batten disease), the next steps (seeking IND status from the FDA for clinical trials), and includes quotes from executives and researchers. This type of announcement, detailing a significant business development, partnership, or licensing agreement that impacts future financing or operations, most closely aligns with a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, since it explicitly details a strategic agreement involving licensing rights and future commercialization, it falls under the scope of significant corporate activity related to capital structure or future revenue streams. Given the options, 'Capital/Financing Update (CAP)' is the most appropriate fit as it describes a major step in securing the rights and pathway for a product, which is a form of corporate financing/value creation activity, although it is not a direct financing announcement. If the document were a formal filing like a 10-K or IR, it would be classified differently. As a press release announcing a strategic deal, CAP is the best fit among the specific choices, though RNS is a possibility if CAP is too narrow. Given the focus on securing exclusive worldwide license and future milestone payments/royalties, CAP is selected over the general RNS.
2019-06-27 English
Theranexus et ' Beyond Batten Disease Foundation ' (BBDF) annoncent un accord de principe pour le développement et la commercialisation du candidat médicament BBDF 101 dans la maladie de Batten
Capital/Financing Update Classification · 95% confidence The document is a press release dated June 27, 2019, announcing a term sheet agreement between Theranexus and the Beyond Batten Disease Foundation (BBDF) regarding the development and commercialization of the drug candidate BBDF 101 for Batten disease. This type of announcement, detailing a strategic partnership, licensing agreement, and future clinical development plans, is characteristic of corporate news releases concerning business development or financing activities. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). Since it specifically details an agreement related to financing/development rights and potential future commercialization, the most fitting category is Capital/Financing Update (CAP), as it outlines a major step in securing the development pathway and commercial rights for a product. Alternatively, given the focus on a strategic agreement, it could be considered a general Regulatory Filing (RNS) if CAP is too narrow, but CAP better captures the essence of securing development/commercialization rights. I will classify it as CAP.
2019-06-27 French
THERANEXUS PARTICIPERA AU HEALTHTECH INVESTOR DAYS (HTID) LES 24 ET 25 JUIN À PARIS
Regulatory Filings Classification · 95% confidence The document is a press release dated June 20, 2019, announcing that the company Theranexus will participate in the HealthTech Investor Days (HTID) on June 24 and 25. It details the nature of the event and the company's goals for attending (meeting investors, highlighting product pipeline milestones). This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed presentation (IP). It is an announcement about an upcoming investor-focused event, which falls best under a general announcement or investor relations communication. Since there is no specific category for 'Investor Event Participation Announcement,' and it is a general communication to the market about company activities aimed at investors, it is best classified as a Regulatory Filing (RNS) as a general announcement, or potentially related to Investor Presentation (IP) if it were the presentation itself, but here it is just the announcement of attendance. Given the nature of the content (announcing participation in an investor conference), RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it is very close to an Investor Relations communication. Given the context of investor engagement, RNS is the safest general classification for a press release announcing participation in an external event.
2019-06-20 French
THERANEXUS INVITED TO JOIN IN THE HEALTHTECH INVESTOR DAYS (HTID) 24 and 25 JUNE IN PARIS
Regulatory Filings Classification · 99% confidence The document is a press release dated June 20, 2019, announcing that Theranexus has been invited to participate in the 'HealthTech Investor Days' event in Paris. It details the company's participation and provides background information about Theranexus. This type of announcement, which informs the market about the company's presence at an investor-focused event, does not fit neatly into the specific financial filing categories like 10-K, ER, or IR. It is a general corporate communication regarding investor relations activities. Since it is not a formal report, a dividend notice, or a management change, the most appropriate general category for corporate announcements that don't fit elsewhere is 'Regulatory Filings' (RNS), as it serves as a broad communication channel to the market about corporate activities, even if not strictly mandated by a specific regulator in the US context, it functions as a general market disclosure.
2019-06-20 English
THERANEXUS ANNOUNCES THE FORMATION OF ITS SCIENTIFIC BOARD
Board/Management Information Classification · 98% confidence The document is titled "THERANEXUS ANNOUNCES THE FORMATION OF ITS SCIENTIFIC BOARD" and details the composition and purpose of this new board, including quotes from the Chief Scientific Officer. This announcement concerns changes in the company's high-level advisory structure, specifically involving scientific leadership and expertise, which aligns directly with the definition of Board/Management Information (MANG). It is not a financial report (10-K, IR, ER), a legal filing, or a general regulatory announcement (RNS).
2019-06-04 English
THERANEXUS ANNONCE LA CONSTITUTION DE SON CONSEIL SCIENTIFIQUE
Board/Management Information Classification · 98% confidence The document is a press release dated June 4, 2019, announcing the composition of Theranexus's Scientific Advisory Board ('THERANEXUS ANNONCE LA CONSTITUTION DE SON CONSEIL SCIENTIFIQUE'). This announcement details changes or additions to key personnel/advisors, specifically experts joining a board. This aligns directly with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management (extended here to include key scientific advisory boards that guide strategy). It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), as it concerns specific governance/personnel structure.
2019-06-04 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.